At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7 enrolled
Drug / intervention
GID SVF-2device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adipose-derived Stromal Vascular Fraction (SVF) Injections to Stimulate Hair Regrowth for Androgenetic Alopecia
In Brief
A clinical study evaluating GID SVF-2 for Androgenetic Alopecia. Completed, enrolled 7 participants across 2 sites.
Detailed Summary
The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF for the treatment of alopecia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAndrogenetic Alopecia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartJul 2016
Primary CompletionJan 2017
TodayJul 2026
First PostedDec 10, 2015
Enrollment StartJul 20, 2016
Primary CompletionJan 22, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.6 years ago
Interventions
GID SVF-2device
Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.